Bladder toxicity risk appears low for psychiatric ketamine patients, though data is limited

A new review of clinical studies suggests that people receiving ketamine for mental health conditions do not face an elevated risk of severe bladder and urinary tract issues, at least in the short term. Researchers noted that while these symptoms are common among recreational users, medically supervised doses appear much safer. The findings were published in the Journal of Psychopharmacology.

Ketamine was synthesized in the early 1960s as a safer alternative to older anesthetics. It offered a shorter duration of effects and a lower risk of delirium. For over fifty years, it has been a staple in operating rooms across the globe. Today, it remains heavily used by surgeons and trauma professionals to induce a loss of consciousness and relieve severe pain.

In recent years, the medical community began exploring the drug for an entirely different purpose. Researchers discovered that providing patients with smaller, subanesthetic doses could rapidly alleviate severe psychiatric distress. It became a popular option for people with treatment-resistant depression, which is a diagnosis given when standard oral antidepressants fail to improve a patient’s mood.

Unlike traditional medications that build up slowly in the brain over weeks, this treatment can improve depressive symptoms within a single day. The drug works by blocking a specific receptor in the brain, triggering a rapid shift in neural circuitry. Because of this fast action, doctors also utilize it to help patients suffering from post-traumatic stress disorder, severe anxiety, and various substance use disorders.

Alongside its medical rise, the drug has a long history of illicit recreational use. Chronic recreational users often take the drug frequently and in massive doses, which can lead to severe organ damage. One of the most common physical complications is a condition known as ketamine-induced urological toxicity.

This urological toxicity involves severe damage to the lower urinary tract. The drug can cause the bladder wall to thicken and contract, reducing the organ’s capacity. Patients with this condition suffer from a constant urge to urinate, pelvic pain, and blood in their urine. In the most severe cases, chronic exposure leads to cellular death in the urinary tract and chronic kidney failure.

Because the antidepressant effects of a single dose generally fade after a few days, psychiatric patients require repeated treatments to maintain their recovery. A standard clinic protocol often involves an intense acute phase of multiple weekly doses, followed by a maintenance phase where patients receive the drug every few weeks. In treatment-resistant cases, this maintenance phase can last for years.

This repeat-dosing schedule mirrors the chronic exposure seen in recreational users. Doctors have expressed concern that psychiatric patients might eventually develop similar bladder and kidney complications. To investigate this risk, lead author Jess Kerr-Gaffney, a researcher at King’s College London, and a team of colleagues conducted a systematic review of the existing medical literature.

A systematic review involves pooling all available published research on a specific topic to identify overarching trends. The research team searched multiple medical databases for clinical trials and observational studies testing the drug in adult psychiatric patients. They specifically looked for any studies that recorded urinary, bladder, or kidney symptoms.

Out of a massive volume of medical literature, the researchers found twenty-seven studies that matched their strict criteria. The vast majority of these studies analyzed patients suffering from severe depressive disorders. The remaining few looked at patients with chronic trauma or generalized anxiety.

Across the twenty-seven studies, the reported rates of urinary symptoms were highly variable. The percentage of patients reporting issues ranged from zero to nearly twenty-five percent. When symptoms did appear, patients generally described them as mild or moderate in severity.

The most common complaint was an increased frequency of urination. Other patients reported a burning sensation while urinating, difficulty emptying their bladder, or producing an unusually large volume of urine. A small number of patients developed bacterial urinary tract infections over the course of their treatment.

To determine if the medication was genuinely at fault, the researchers compared the treatment groups to control groups. In the randomized controlled trials they reviewed, the rate of urological complaints among patients taking the drug was usually equal to or lower than the rate seen in the control groups. The control groups typically received an inactive placebo or an alternative medication.

There were a few minor exceptions in the data. Esketamine is a purified, highly potent variation of the drug delivered through a nasal spray. In three trials testing this nasal spray, patients reported slightly higher rates of urinary symptoms than those taking a placebo, though the results were not statistically significant. Another trial indicated that patients given flexible, varying doses reported slightly more side effects than those on a rigid schedule.

A few of the reviewed studies took a more objective approach by testing patient urine in a laboratory. Scientists checked the urine for microscopic warning signs, such as stray red blood cells, white blood cells, and elevated protein content. These continuous lab measurements remained stable across the treatment timeline, showing no hidden signs of cellular damage.

Despite these reassuring results, the research team highlighted several severe limitations in the available evidence. The most prominent issue involves the short timeframes used by modern clinical trials. The median follow-up period across the reviewed studies was only four weeks.

In recreational users, toxicity usually develops after months or years of chronic exposure to the chemical. A patient beginning a new psychiatric routine is highly unlikely to develop visible bladder damage within a single month. Only five studies in the entire review tracked patients for more than six months. Based on this limited data, the researchers concluded there is not enough evidence to guarantee that long-term maintenance therapy is entirely safe for the bladder.

The review also exposed major flaws in how clinical trials monitor physical safety. Eleven of the included studies did not use any structured assessments for urinary health. They simply utilized passive monitoring, meaning doctors waited for patients to volunteer complaints about side effects.

Passive tracking is often inadequate for detecting gradual organ damage. A patient might dismiss minor bladder irritation as a natural sign of aging or fail to connect it to their mental health treatment. Unstructured monitoring can easily result in an underestimation of the true physical risks.

When evaluating the quality of the data, the review team found additional problems. Only fifteen percent of the included studies were rated as having a low risk of bias. Many trials were unblinded, meaning the patients knew they were receiving an active, powerful medication.

This lack of blinding is dangerous because the drug acts as a highly effective painkiller. If the medication is actively numbing the body, patients might not register the early, subtle pain of bladder inflammation. A subjective questionnaire could miss the initial stages of tissue damage entirely if the patient’s pain receptors are blocked.

These blind spots in the medical literature are becoming a pressing issue due to changes in modern healthcare. Telehealth platforms and medical startups now offer at-home treatments for various mental health conditions. Patients are increasingly receiving these prescriptions via the mail, consuming them outside the direct supervision of a traditional clinical environment.

Many of these at-home chemical formulations are not formally approved by the Food and Drug Administration. Patients using unregulated products at home might take the drug for extended periods without receiving systematic safety examinations. This creates a scenario where early signs of organ damage could slide completely under the radar.

Moving forward, the research team recommended that all future clinical trials include active, mandatory screening for urinary side effects. Clinic staff should utilize standardized bladder pain questionnaires on a weekly basis to track subtle changes in patient comfort. Relying on patients to spontaneously report their pain is no longer considered a sufficient safety measure.

They also suggested implementing regular laboratory urine tests before and after treatment sessions. Checking for microscopic biomarkers is a cheap, non-invasive method for detecting invisible tissue damage before a patient feels any physical discomfort. Adding these objective measurements would drastically improve the accuracy of safety monitoring and help protect vulnerable psychiatric patients from long-term harm.

The study, “Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review,” was authored by Jess Kerr-Gaffney, Anna Tröger, Alice Caulfield, Philipp Ritter, James Rucker, and Allan H. Young.